Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs & Therapy Perspectives
Published in: Drugs & Therapy Perspectives 7/2003

01-07-2003 | Disease Management

Treatment of molluscum contagiosum is more difficult in immune compromised patients

Published in: Drugs & Therapy Perspectives | Issue 7/2003

Login to get access

Excerpt

Molluscum contagiosum virus (MCV) is a human-specific poxvirus causing cutaneous and, rarely, mucosal, lesions. It is transmitted by direct skin-to-skin contact. MCV does not develop latency but has many mechanisms to evade and subvert the immune responses of the host. In mild cases, MCV may clear spontaneously. When therapy is required, destructive methods, cytotoxic agents, antivirals and immune modulators are available. All have all been used, with variable success, to treat patients with MCV. The virus is the most difficult to treat in patients with immune dysregulation and/or immune suppression, such as those who also have HIV-1 infection. …
Literature
1.
Smith KJ, Skelton H. Molluscum contagiosum: recent advances in pathogenic mechanisms, and new therapies. Am J Clin Dermatol 2002; 3(8): 535–45PubMedCrossRef
2.
Smith KJ, Yeager J, Skelton H. Molluscum contagiosum: its clinical, histopathologic, and immunohistochemical spectrum. Int J Dermatol 1999; 38: 664–72PubMedCrossRef
3.
Bugert JJ, Darai G. Recent advances in molluscum contagiosum virus research. Arch Virol 1997; 13: 35–47
4.
Born TL, Morrison LA, Esteban DJ, et al. A poxvirus protein that binds to and inactivates IL-18, and inhibits NK cell responses. J Immunol 2000; 164: 3246–54PubMed
5.
Romiti R, Ribeiro AP, Grinblat BM, et al. Treatment of molluscum contagiosum with potassium hydroxide: a clinical approach in 35 children. Pediatr Dermatol 1999; 16: 228–31PubMedCrossRef
6.
Ronnerfalt L, Fransson J, Wahlgren CF. EMLA cream provides rapid pain relief for the curettage of molluscum contagiosum in children with atopic dermatitis without causing serious application site reactions. Pediatr Dermatol 1998; 15: 309–12PubMedCrossRef
7.
Bucalo BD, Mirikitani EJ, Moy RL. Comparison of skin anesthetic effect of liposomal lidocaine, nonliposomal lidocaine and EMLA using 30-minute application time. Dermatol Surg 1998; 24: 537–41PubMedCrossRef
8.
De Clercq E. Therapeutic potential of cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox-, and adenovirus) infections. Verh K Acad Geneeskd Belg 1996; 58: 19–47PubMed
9.
10.
Zabawski EJ, Cockerell CJ. Topical cidofovir for molluscum contagiosum in children. Pediatr Dermatol 1999; 16: 414–5PubMed
11.
Toro JR, Wood LV, Patel NK, et al. Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Arch Dermatol 2000; 136: 983–5PubMedCrossRef
12.
Meadows KP, Tyring SK, Pavia AT, et al. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients with cidofovir. Arch Dermatol 1997; 133: 987–90PubMedCrossRef
13.
Urdiales JL, Morata P, Nunez I, et al. Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett 1996; 102: 31–7PubMedCrossRef
14.
Hwang Y, Rowley D, Rhodes D, et al. Mechanism of inhibition of a poxvirus topoisomerase by the marine natural product sansalvamide A. Mol Pharmacol 1999; 55: 1049–53PubMed
15.
Hourihane J, Hodges E, Smith J, et al. Interferon alpha treatment of molluscum contagiosum in immunodeficiency patients. Arch Dis Child 1999; 80: 77–9PubMedCrossRef
16.
Gross G, Roussaki A, Brzoska J. Recalcitrant molluscum contagiosum in a patient with AIDS successfully treated by a combination of CO2 laser and natural interferon beta gel. Arch Derm Venereol 1998; 78: 309–10CrossRef
17.
Dohil M, Prendiville JS. Treatment of molluscum contagiosum with oral cimetidine: clinical experience in 13 patients. Pediatr Dermatol 1996; 15: 71–2
18.
Syed TA, Goswani J, Ahmadpur A, et al. Treatment of molluscum contagiosum in males with an analog of imiquimod 1% cream: a placebo-controlled, double blind study. J Dermatol 1998; 25: 309–13PubMed
19.
Liota E, Smith KJ, Buckley R, et al. Imiquimod therapy for molluscum contagiosum. J Cutan Med Surg 2000; 4: 76–82PubMed
20.
Buckley R, Smith K. Topical imiquimod therapy for chronic giant molluscum contagiosum in a patient with advanced human immunodeficiency virus I disease. Arch Dermatol 1999; 135: 1167–9PubMedCrossRef
21.
Calista D, Boschini A, Landi G. Resolution of disseminated molluscum contagiosum with highly active anti-retroviral therapy (HAART) in patients with AIDS. Eur J Dermatol 1999; 9: 211–3PubMed
Metadata
Title
Treatment of molluscum contagiosum is more difficult in immune compromised patients
Publication date
01-07-2003
Publisher
Springer International Publishing
Published in
Drugs & Therapy Perspectives / Issue 7/2003
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI
https://doi.org/10.2165/00042310-200319070-00004

Other articles of this Issue 7/2003

Drugs & Therapy Perspectives 7/2003 Go to the issue

Disease Management

Ocular allergy: avoidance of allergens and symptomatic therapy still the mainstay of treatment for most patients

Drugs and Profile Reports

Pneumococcal 7-valent conjugate vaccine protects young children

Product Introductions

New in the marketplace

Drugs and Profile Reports

Imatinib Mesylate in GIST: profile report

Practical Issues and Updates

The usefulness of splitting tablets as a cost-saving strategy is limited

Disease Management

The treatment of alcohol use disorders in adolescents requires greater research